XOMA Royalty (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

XOMA Royalty Corporation (NASDAQ:XOMA)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $29.96 and traded as high as $35.04. XOMA Royalty shares last traded at $34.58, with a volume of 213,288 shares trading hands.

Analyst Ratings Changes

Several equities analysts have weighed in on XOMA shares. Zacks Research lowered shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 10th. Benchmark reiterated a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $97.00 target price on shares of XOMA Royalty in a report on Friday, March 20th. TD Cowen upgraded shares of XOMA Royalty to a “hold” rating in a report on Friday, February 13th. Finally, Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $61.60.

XOMA Royalty Stock Performance

The firm’s fifty day moving average price is $27.20 and its 200 day moving average price is $29.96. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $412.19 million, a price-to-earnings ratio of 23.69 and a beta of 0.68.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. The firm had revenue of $13.76 million for the quarter, compared to analyst estimates of $11.13 million. Analysts forecast that XOMA Royalty Corporation will post -1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA Royalty

Several large investors have recently made changes to their positions in the stock. Opaleye Management Inc. lifted its holdings in shares of XOMA Royalty by 14.7% in the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after acquiring an additional 37,503 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in XOMA Royalty during the 4th quarter worth approximately $237,000. Panagora Asset Management Inc. lifted its holdings in XOMA Royalty by 24.2% during the 4th quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock worth $564,000 after buying an additional 4,135 shares in the last quarter. Barclays PLC lifted its holdings in XOMA Royalty by 12.1% during the 4th quarter. Barclays PLC now owns 14,822 shares of the biotechnology company’s stock worth $394,000 after buying an additional 1,598 shares in the last quarter. Finally, State Street Corp lifted its holdings in XOMA Royalty by 4.7% during the 4th quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock worth $4,651,000 after buying an additional 7,873 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.